This approval now allows Ethex Corporation, KV’s wholly-owned generic/non-branded subsidiary, to offer a full line of all strengths of this product.
Ethex Corporation has commenced the launch of these two new strengths into its current line of 15mg, 30mg and 60mg morphine extended release tablets. The company believes these two strengths will be a positive addition and will allow Ethex to increase its market share position for its full product line offering.
KV said that while this is a highly genericized market, these two strengths have shown unit market growth year-over-year, according to IMS.